UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Tumor cell expression of vascular endothelial growth factor receptor 2 is an adverse prognostic factor in patients with squamous cell carcinoma of the lung

PloS one, 2013-11, Vol.8 (11), p.e80292-e80292

2013

Volltextzugriff (PDF)

Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study

Annals of oncology, 2018-03, Vol.29 (3), p.602-609

2018

Volltextzugriff (PDF)

Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab

British journal of cancer, 2016-10, Vol.115 (8), p.974-982

2016

Volltextzugriff (PDF)

3073 Exploratory analysis of frontline therapies in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) versus DOC for the treatment of stage IV non-small-cell lung cancer (NSCLC) after disease progression on platinum-based therapy

European journal of cancer (1990), 2015-09, Vol.51, p.S621-S621

2015

Volltextzugriff (PDF)

Gemcitabine as First-Line Therapy in Patients with Metastatic Breast Cancer: A Phase II Trial

Oncology, 2002-01, Vol.62 (1), p.2-8

2002

Volltextzugriff (PDF)

Phase I Study of a Third-Generation Selective Estrogen Receptor Modulator, LY353381.HCl, in Metastatic Breast Cancer

Journal of clinical oncology, 2001-04, Vol.19 (7), p.2002-2009

2001

Volltextzugriff (PDF)

Activation of the Mitogen-Activated Protein Kinase Pathway Is Involved in and Sufficient for Megakaryocytic Differentiation of CMK Cells

Blood, 1997-11, Vol.90 (9), p.3462-3470

1997

Volltextzugriff (PDF)

A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma

Gynecologic oncology, 2005-02, Vol.96 (2), p.374-380

2005

Volltextzugriff (PDF)

P11.46.A ACTION: A RANDOMIZED PHASE 3 STUDY OF DORDAVIPRONE (ONC201) IN PATIENTS WITH NEWLY DIAGNOSED H3 K27M-MUTANT DIFFUSE GLIOMA

Neuro-oncology (Charlottesville, Va.), 2023-09, Vol.25 (Supplement_2), p.ii84-ii84

2023

Volltextzugriff (PDF)

Potential role of hematopoietic stem cell transplantation in children with secondary acute lymphocytic leukemia

Bone marrow transplantation (Basingstoke), 2002, Vol.29 (2), p.173-175

2002

Volltextzugriff (PDF)

Phase III study of gemcitabine (G) plus paclitaxel (T) versus T in patients with metastatic breast cancer (MBC) – Post-study chemotherapy (PSC) trend analysis

European journal of cancer supplements, 2008, Vol.6 (7), p.217-217

2008

Volltextzugriff (PDF)

Olaratumab for the treatment of patients (pts) with advanced/metastatic soft tissue sarcoma (STS): Treatment patterns in the United States (US) during the first year post-approval

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e23535-e23535

2018

Volltextzugriff (PDF)

A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer

Gynecologic oncology, 2003-07, Vol.90 (1), p.64-69

2003

Volltextzugriff (PDF)

Phase II trial of pemetrexed in children with refractory solid tumors: A Children's Oncology Group study

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.9535-9535

2010

Volltextzugriff (PDF)

Homocysteine (HC) level as possible predictor of pemetrexed efficacy

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.20078-20078

2006

Volltextzugriff (PDF)

Extranodal spread of anaplastic large cell (CD30+) lymphoma presenting as a cutaneous perivascular infiltrate

Journal of cutaneous pathology, 1996-08, Vol.23 (4), p.323-327

1996

Volltextzugriff (PDF)

Gemcitabine plus paclitaxel and gemcitabine plus docetaxel in first- or second-line metastatic breast cancer: A phase II randomized trial

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.1046-1046

2007

Volltextzugriff (PDF)

Phase II, Randomized, Double-Blind Study of Two Dose Levels of Arzoxifene in Patients With Locally Advanced or Metastatic Breast Cancer

Journal of clinical oncology, 2003-03, Vol.21 (6), p.1007-1014

2003

Volltextzugriff (PDF)

Candidate biomarker analyses in gastric or gastro-esophageal junction carcinoma: REGARD trial of single-agent ramucirumab (RAM) vs. placebo (PL)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.4029-4029

2015

Volltextzugriff (PDF)

A phase II study of pemetrexed and doxorubicin in patients with advanced or metastatic breast cancer (MBC)

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.1047-1047

2007

Volltextzugriff (PDF)

Randomized, phase II study of two doses of pemetrexed as first-line chemotherapy for locally advanced or metastatic breast cancer (MBC): Clinical results and exploratory pharmacogenomic analysis

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.3077-3077

2006

Volltextzugriff (PDF)

Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): Quality of life (QoL) and pain palliation results from the global phase III study

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.621-621

2004

Volltextzugriff (PDF)

Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): Quality of life (QoL) and pain palliation results from the global phase III study

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.621-621

2004

Volltextzugriff (PDF)

Final report of a phase I clinical study of biweekly pemetrexed and gemcitabine in patients with advanced solid tumors: Second dosing schedule & response

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.7257-7257

2005

Volltextzugriff (PDF)

1 – 25 von 116

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(101)
Mit Volltextzugriff
(96)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(48)
Humans
(40)
Life Sciences & Biomedicine
(38)
Oncology
(31)
Female
(30)
Adult
(22)
Aged
(22)
Middle Aged
(22)
Male
(17)
Biological And Medical Sciences
(15)
Medical Sciences
(14)
Treatment Outcome
(14)
Aged, 80 And Over
(13)
Breast Neoplasms - Drug Therapy
(12)
Double-Blind Method
(11)
Tumors
(11)
Guanine - Analogs & Derivatives
(10)
Pemetrexed
(10)
Chemotherapy
(9)
Glutamates - Administration & Dosage
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer

Tumor cell expression of vascular endothelial growth factor receptor 2 is an adverse prognostic factor in patients with squamous cell carcinoma of the lung

Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study

Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab

3073 Exploratory analysis of frontline therapies in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) versus DOC for the treatment of stage IV non-small-cell lung cancer (NSCLC) after disease progression on platinum-based therapy

Gemcitabine as First-Line Therapy in Patients with Metastatic Breast Cancer: A Phase II Trial

Phase I Study of a Third-Generation Selective Estrogen Receptor Modulator, LY353381.HCl, in Metastatic Breast Cancer

Activation of the Mitogen-Activated Protein Kinase Pathway Is Involved in and Sufficient for Megakaryocytic Differentiation of CMK Cells

A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma

P11.46.A ACTION: A RANDOMIZED PHASE 3 STUDY OF DORDAVIPRONE (ONC201) IN PATIENTS WITH NEWLY DIAGNOSED H3 K27M-MUTANT DIFFUSE GLIOMA

Potential role of hematopoietic stem cell transplantation in children with secondary acute lymphocytic leukemia

Phase III study of gemcitabine (G) plus paclitaxel (T) versus T in patients with metastatic breast cancer (MBC) – Post-study chemotherapy (PSC) trend analysis

Olaratumab for the treatment of patients (pts) with advanced/metastatic soft tissue sarcoma (STS): Treatment patterns in the United States (US) during the first year post-approval

A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer

Phase II trial of pemetrexed in children with refractory solid tumors: A Children's Oncology Group study

Homocysteine (HC) level as possible predictor of pemetrexed efficacy

Extranodal spread of anaplastic large cell (CD30+) lymphoma presenting as a cutaneous perivascular infiltrate

Gemcitabine plus paclitaxel and gemcitabine plus docetaxel in first- or second-line metastatic breast cancer: A phase II randomized trial

Phase II, Randomized, Double-Blind Study of Two Dose Levels of Arzoxifene in Patients With Locally Advanced or Metastatic Breast Cancer

Candidate biomarker analyses in gastric or gastro-esophageal junction carcinoma: REGARD trial of single-agent ramucirumab (RAM) vs. placebo (PL)

A phase II study of pemetrexed and doxorubicin in patients with advanced or metastatic breast cancer (MBC)

Randomized, phase II study of two doses of pemetrexed as first-line chemotherapy for locally advanced or metastatic breast cancer (MBC): Clinical results and exploratory pharmacogenomic analysis

Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): Quality of life (QoL) and pain palliation results from the global phase III study

Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): Quality of life (QoL) and pain palliation results from the global phase III study

Final report of a phase I clinical study of biweekly pemetrexed and gemcitabine in patients with advanced solid tumors: Second dosing schedule & response

Suchergebnisse filtern